Abstract
The combination of fixed doses (CDF) of empagliflozin and linagliptin (EMPA / LINA) includes a type 2 sodium-glucose (ISGLT2) and a dipeptidylpeptidase inhibitor type-4 (IDPP4) inhibitor. It is indicated as an adjunct to the diet in patients with diabetes mellitus type 2 (DM2) with poor control, treated with metformin and / or sulfonylurea and one of the CDF components or pretreated patients with the two monocomponents.
Keywords
Diabetes mellitus type 2; Empagliflozin; Linagliptin; Combination
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Empagliflozina/linagliptina per al tractament de la diabetis mellitus tipus 2. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4176This item appears in following collections
The following license files are associated with this item: